<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240171</url>
  </required_header>
  <id_info>
    <org_study_id>Dapagliflozin in T2DM</org_study_id>
    <nct_id>NCT04240171</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Comparative Study of Dapagliflozin Versus Glimepiride Effect on Insulin Regulated Aminopeptidase (IRAP) and Interleukin-34 (IL-34) in Patient With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research objectives:

      The aim of the study to check the effect of Dapagliflozin versus Glimepiride on insulin
      regulated aminopeptidase (IRAPe) and interleukin-34 (IL-34) in patients with type 2 diabetes
      mellitus, and associated it with insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method and proposal steps:

        1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,
           Damanhour University.

        2. All participant agreed to take part in this clinical study and provide informed consent.

        3. 60 Patients with type 2 DM will be enrolled Internal Medicine Department, Tanta
           University Hospital.

        4. Serum samples will be collected for measuring the biomarkers.

        5. All enrolled 60 patients will be mentioned as two groups; Group 1(n=30): are the
           patients who are prescribed dapagliflozin to control their blood sugar level. Group 2
           (n=30): are the patients who are prescribed glimepiride

        6. All patients will be followed up during 3 months' period.

        7. At the end of 3 months, step 4 will be repeated.

        8. Statistical tests appropriate to the study design will be conducted to evaluate the
           significance of the results.

        9. Measuring outcomes: the primary outcome is the change from baseline to post-treatment
           insulin sensitivity reflected by change of serum level of measured marker after 3
           months.

       10. Results, discussion, conclusion, and recommendations will be given.

      Methodology:

        1. Fasting blood glucose (FBG) 2 hrs. post prandial blood glucose(2hPPBG) will be measured
           by glucometer.

        2. HbA1c %, Fasting plasma insulin (FPI), Interleukin-34 (IL-34), and extracellular domain
           of insulin regulated aminopeptidase (IRAPe) will be assayed by Enzyme-Linked
           Immunosorbent Assay (ELISA).

        3. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Blood Sugar</measure>
    <time_frame>three months</time_frame>
    <description>serum blood glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c %</measure>
    <time_frame>three months</time_frame>
    <description>Glycated Hemoglobin</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>dapagliflozin</arm_group_label>
    <description>Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <description>Group 2 (n=30): are the patients who are prescribed glimepiride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 5Mg Tab</intervention_name>
    <description>Dapagliflozin 5mg tablets daily</description>
    <arm_group_label>dapagliflozin</arm_group_label>
    <other_name>Diglifloz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride 4Mg Tab</intervention_name>
    <description>Glimepiride Tablets daily</description>
    <arm_group_label>glimepiride</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        3- 60 Patients with type 2 DM will be enrolled Internal Medicine Department, Tanta
        University Hospital.

        4- Serum samples will be collected for measuring the biomarkers. All enrolled 60 patients
        will be mentioned as two groups; Group 1(n=30): are the patients who are prescribed
        dapagliflozin to control their blood sugar level. Group 2 (n=30): are the patients who are
        prescribed glimepiride

          -  All patients will be followed up during 3 months' period.

          -  At the end of 3 months, step 4 will be repeated.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 60 Patients with type 2 DM diagnosed clinically. The age ranged from 18 to 70 years.
             There are no limits to the duration of DM and gender.

          2. HbA1c ≥ 7

        Exclusion Criteria:

          1. Other types of DM

          2. Hypersensitivity to the drug

          3. Abnormal liver function

          4. Patients with renal impairment (eGFR ≤ 60 ml/min)

          5. Previous history of bladder cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashwa EL-Gharabawy, Lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rehab Werida</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab Werida, Lecturer</last_name>
    <phone>+201005359968</phone>
    <email>rehabwrieda@pharm.dmu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nashwa EL-Gharabawy, Lecturer</last_name>
    <email>nashwa.elgharbawy@med.tanta.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.</citation>
    <PMID>24320621</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015 Dec 1;309(11):F889-900. doi: 10.1152/ajprenal.00267.2015. Epub 2015 Sep 9. Review.</citation>
    <PMID>26354881</PMID>
  </results_reference>
  <results_reference>
    <citation>Davidson JA, Kuritzky L. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.</citation>
    <PMID>25414933</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Clinical Pharmacy Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

